NCCN guidelines recommend the evaluation of tumor gene status, including KRAS/NRAS and BRAF mutations, as well as HER2 amplification and microsatellite instability (MSI)/mismatch repair (MMR) status, for the systemic treatment of advanced or mCRC45. The gene discussed is NRAS; the disease is neoplasm.